Carisma Therapeutics Inc
CARM0.154USD
0.000
Close 11/04, 16:00（ET）Quotes delayed by 15 min
6.43MMarket Cap
LossP/E TTM
More Details of Carisma Therapeutics Inc Company
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the treatment of solid tumors. Its first product candidate, CT-0508, is an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). Its second product candidate, CT-0525, is an ex vivo gene-modified autologous chimeric antigen receptor-macrophage (CAR-Macrophage) cellular therapy intended to treat solid tumors that overexpress HER2. CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors.
Carisma Therapeutics Inc Info
Ticker SymbolCARM
Company nameCarisma Therapeutics Inc
IPO dateFeb 06, 2014
CEOMr. Steven (Steve) Kelly
Number of employees46
Security typeOrdinary Share
Fiscal year-endFeb 06
Address3675 Market Street
CityPHILADELPHIA
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code19104
Phone12674916422
Websitehttps://sesenbio.com/
Ticker SymbolCARM
IPO dateFeb 06, 2014
CEOMr. Steven (Steve) Kelly
Company Executives of Carisma Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Natalie Mcandrew
Ms. Natalie Mcandrew
Vice President - Finance
Vice President - Finance
--
--
Mr. Sanford (Sandy) Zweifach, CPA
Mr. Sanford (Sandy) Zweifach, CPA
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Mr. Steven (Steve) Kelly
Mr. Steven (Steve) Kelly
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Marella Thorell
Ms. Marella Thorell
Director
Director
--
--
Ms. Sohanya Cheng
Ms. Sohanya Cheng
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Natalie Mcandrew
Ms. Natalie Mcandrew
Vice President - Finance
Vice President - Finance
--
--
Mr. Sanford (Sandy) Zweifach, CPA
Mr. Sanford (Sandy) Zweifach, CPA
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Mr. Steven (Steve) Kelly
Mr. Steven (Steve) Kelly
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Marella Thorell
Ms. Marella Thorell
Director
Director
--
--
Ms. Sohanya Cheng
Ms. Sohanya Cheng
Director
Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sun, Oct 5
Updated: Sun, Oct 5
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Modernatx Inc
12.11%
Longview Innovation Corp
6.49%
Wellington Partners Venture Capital GmbH
5.50%
SymBiosis Capital Management, LLC
5.30%
Abbvie Biotechnology Ltd
4.44%
Other
66.16%
Shareholders
Shareholders
Proportion
Modernatx Inc
12.11%
Longview Innovation Corp
6.49%
Wellington Partners Venture Capital GmbH
5.50%
SymBiosis Capital Management, LLC
5.30%
Abbvie Biotechnology Ltd
4.44%
Other
66.16%
Shareholder Types
Shareholders
Proportion
Corporation
26.57%
Venture Capital
12.52%
Endowment Fund
3.00%
Investment Advisor
2.06%
Investment Advisor/Hedge Fund
0.98%
Hedge Fund
0.83%
Research Firm
0.41%
Individual Investor
0.03%
Other
53.60%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
139
8.27M
19.80%
-5.45M
2025Q2
146
24.87M
59.52%
-2.75M
2025Q1
156
25.29M
60.52%
-3.29M
2024Q4
182
25.53M
61.15%
+1.71M
2024Q3
188
25.07M
60.04%
+333.42K
2024Q2
201
25.99M
62.34%
-714.53K
2024Q1
197
28.41M
69.12%
+11.20M
2023Q4
204
28.90M
71.07%
+15.30M
2023Q3
225
26.71M
66.30%
+15.24M
2023Q2
236
26.87M
66.72%
+19.76M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Modernatx Inc
5.06M
12.11%
--
--
Jul 31, 2025
Longview Innovation Corp
2.71M
6.49%
--
--
Jul 31, 2025
Wellington Partners Venture Capital GmbH
2.30M
5.5%
--
--
Jul 31, 2025
SymBiosis Capital Management, LLC
2.22M
5.3%
--
--
Jul 31, 2025
Abbvie Biotechnology Ltd
1.86M
4.44%
-893.98K
-32.51%
Mar 31, 2025
Merck & Co Inc
1.47M
3.53%
--
--
Jun 30, 2025
University of Pennsylvania Trustees
1.25M
3%
--
--
Sep 30, 2024
Aju IB Investment Co., Ltd.
718.33K
1.72%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
350.32K
0.84%
-1.05M
-74.90%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
336.79K
0.81%
-64.84K
-16.14%
Jun 30, 2025
View more
Related ETFs
Updated: Sun, Nov 2
Updated: Sun, Nov 2
Name
Proportion
Avantis US Small Cap Equity ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
Global X Russell 2000 Covered Call ETF
0%
iShares Russell 2000 ETF
0%
Invesco Russell 2000 Dynamic Multifactor ETF
0%
iShares Russell 2000 Value ETF
0%
ProShares UltraPro Russell2000
0%
Global X Russell 2000 ETF
0%
iShares Micro-Cap ETF
0%
Proshares Ultra Russell 2000
0%
View more
Avantis US Small Cap Equity ETF
Proportion0%
DFA Dimensional US Core Equity Market ETF
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Invesco Russell 2000 Dynamic Multifactor ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Global X Russell 2000 ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Mar 06, 2023
Merger
20→1
Mar 06, 2023
Merger
20→1
Mar 06, 2023
Merger
20→1
Mar 06, 2023
Merger
20→1
Date
Type
Ratio
Mar 06, 2023
Merger
20→1
Mar 06, 2023
Merger
20→1
Mar 06, 2023
Merger
20→1
Mar 06, 2023
Merger
20→1
